Revenues (Tables)

3 Months Ended

Mar. 31, 2022

Revenue from Contract with Customer [Abstract]

Disaggregation of revenue by product and by geographic area

Revenues were as follows (in millions):

	Three months ended March 31,
	2022						2021
	U.S.		ROW		Total		U.S.		ROW		Total
Enbrel	$	843	$	19	$	862	$	894	$	30	$	924
Prolia	582		270		852		501		257		758
XGEVA	368		134		502		334		134		468
Otezla	350		101		451		366		110		476
Aranesp	137		221		358		125		230		355
Neulasta	304		44		348		421		61		482
Repatha	165		164		329		139		147		286
KYPROLIS	196		91		287		159		92		251
Nplate	156		110		266		112		115		227
Other products	936		540		1,476		852		513		1,365
Total product sales(1)	$	4,037	$	1,694	5,731		$	3,903	$	1,689	5,592
Other revenues					507						309
Total revenues					$	6,238					$	5,901

____________

(1)    Hedging gains and losses, which are included in product sales, were not material for the three months ended March 31, 2022 and 2021.